Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy
A novel risk assessment method, Japan Cancer of the Prostate Risk Assessment, has been developed based on database of patients receiving primary androgen deprivation therapy. To investigate the usefulness of Japan Cancer of the Prostate Risk Assessment for non-metastatic, high-risk prostate cancer p...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of clinical oncology 2014-04, Vol.44 (4), p.360-365 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 365 |
|---|---|
| container_issue | 4 |
| container_start_page | 360 |
| container_title | Japanese journal of clinical oncology |
| container_volume | 44 |
| creator | Akakura, Koichiro Tsuji, Hiroshi Suzuki, Hiroyoshi Ichikawa, Tomohiko Ishikawa, Hitoshi Okada, Tohru Kamada, Tadashi Harada, Masaoki Tsujii, Hirohiko Shimazaki, Jun |
| description | A novel risk assessment method, Japan Cancer of the Prostate Risk Assessment, has been developed based on database of patients receiving primary androgen deprivation therapy. To investigate the usefulness of Japan Cancer of the Prostate Risk Assessment for non-metastatic, high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Patients with non-metastatic, high-risk prostate cancer (T3, initial prostate specific antigen level ≥20 ng/ml, and/or Gleason score ≥8) were included. The patients were treated with carbon ion radiotherapy (the total dose from 57.6 Gy (relative biological effectiveness)/16 fractions to 66.0 Gy(relative biological effectiveness)/20 fractions), and neoadjuvant as well as adjuvant androgen deprivation therapy for at least 24 months.
Four hundred and twenty-six patients were included with the median follow-up of 68.1 months. Of 426, 210 (49.3%), 270 (63.4%) and 251 (58.9%) had Gleason 8-10, prostate specific antigen ≥20 ng/ml and T3, respectively. The 10-year progression-free and cause-specific survival rates in Japan Cancer of the Prostate Risk Assessment 1-2 group (76.5 and 98.9%) were significantly better than those in Japan Cancer of the Prostate Risk Assessment 3-6 group (52.6 and 93.1%), (P < 0.001 and P = 0.044, respectively). The median progression-free survivals in the Japan Cancer of the Prostate Risk Assessment 1-2 and 3-6 groups were 158.9 months and 125.9 months (95% confidence interval: 108.6-143.2 months), respectively.
For non-metastatic, high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy, Japan Cancer of the Prostate Risk Assessment score was useful for predicting the progression-free and cause-specific survivals. |
| doi_str_mv | 10.1093/jjco/hyu006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1512556770</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1512556770</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-ab4f986c21e559d9287ce7a1b589be92533d52bb764cf26c8b26639184bc94483</originalsourceid><addsrcrecordid>eNo9kE1r3DAQhkVoaLZpT7kXHQvFib4tHZelXyHQEJqzkeRx7K3XciQ5YX9C_nUVdtPDMDDz8DLzIHRBySUlhl9ttz5c9fuFEHWCVlQoWXHF6Du0IlzpimlKz9CHlLaEEKlF_R6dMSG1NJyu0Mt9gm4ZJ0gJhw5fV5v17d0aJx8i4C5E3A8PfRWH9BfPMaRsM2BvJw8RzzYPMOWEc4QybvHzkPuyjC5MeCgVbTuE3EO08x7P45KwndoYHmDCLcxxeCoBBTsSH9FpZ8cEn479HN1___Zn87O6-f3j12Z9U3luRK6sE53RyjMKUprWMF17qC11UhsHhknOW8mcq5XwHVNeO6YUN1QL540Qmp-jL4fc8s_jAik3uyF5GEc7QVhSQyVlUqq6JgX9ekB9eT1F6Jpy9c7GfUNJ8-q-eXXfHNwX-vMxeHE7aP-zb7L5P9Vbg0g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1512556770</pqid></control><display><type>article</type><title>Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Akakura, Koichiro ; Tsuji, Hiroshi ; Suzuki, Hiroyoshi ; Ichikawa, Tomohiko ; Ishikawa, Hitoshi ; Okada, Tohru ; Kamada, Tadashi ; Harada, Masaoki ; Tsujii, Hirohiko ; Shimazaki, Jun</creator><creatorcontrib>Akakura, Koichiro ; Tsuji, Hiroshi ; Suzuki, Hiroyoshi ; Ichikawa, Tomohiko ; Ishikawa, Hitoshi ; Okada, Tohru ; Kamada, Tadashi ; Harada, Masaoki ; Tsujii, Hirohiko ; Shimazaki, Jun</creatorcontrib><description>A novel risk assessment method, Japan Cancer of the Prostate Risk Assessment, has been developed based on database of patients receiving primary androgen deprivation therapy. To investigate the usefulness of Japan Cancer of the Prostate Risk Assessment for non-metastatic, high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Patients with non-metastatic, high-risk prostate cancer (T3, initial prostate specific antigen level ≥20 ng/ml, and/or Gleason score ≥8) were included. The patients were treated with carbon ion radiotherapy (the total dose from 57.6 Gy (relative biological effectiveness)/16 fractions to 66.0 Gy(relative biological effectiveness)/20 fractions), and neoadjuvant as well as adjuvant androgen deprivation therapy for at least 24 months.
Four hundred and twenty-six patients were included with the median follow-up of 68.1 months. Of 426, 210 (49.3%), 270 (63.4%) and 251 (58.9%) had Gleason 8-10, prostate specific antigen ≥20 ng/ml and T3, respectively. The 10-year progression-free and cause-specific survival rates in Japan Cancer of the Prostate Risk Assessment 1-2 group (76.5 and 98.9%) were significantly better than those in Japan Cancer of the Prostate Risk Assessment 3-6 group (52.6 and 93.1%), (P < 0.001 and P = 0.044, respectively). The median progression-free survivals in the Japan Cancer of the Prostate Risk Assessment 1-2 and 3-6 groups were 158.9 months and 125.9 months (95% confidence interval: 108.6-143.2 months), respectively.
For non-metastatic, high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy, Japan Cancer of the Prostate Risk Assessment score was useful for predicting the progression-free and cause-specific survivals.</description><identifier>ISSN: 0368-2811</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hyu006</identifier><identifier>PMID: 24585931</identifier><language>eng</language><publisher>England</publisher><subject>Aged ; Aged, 80 and over ; Androgen Antagonists - therapeutic use ; Antineoplastic Agents, Hormonal - therapeutic use ; Biomarkers, Tumor - blood ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Heavy Ion Radiotherapy ; Humans ; Japan ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoadjuvant Therapy - methods ; Neoplasm Grading ; Predictive Value of Tests ; Prognosis ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - therapy ; Risk Assessment ; Risk Factors</subject><ispartof>Japanese journal of clinical oncology, 2014-04, Vol.44 (4), p.360-365</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-ab4f986c21e559d9287ce7a1b589be92533d52bb764cf26c8b26639184bc94483</citedby><cites>FETCH-LOGICAL-c394t-ab4f986c21e559d9287ce7a1b589be92533d52bb764cf26c8b26639184bc94483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24585931$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akakura, Koichiro</creatorcontrib><creatorcontrib>Tsuji, Hiroshi</creatorcontrib><creatorcontrib>Suzuki, Hiroyoshi</creatorcontrib><creatorcontrib>Ichikawa, Tomohiko</creatorcontrib><creatorcontrib>Ishikawa, Hitoshi</creatorcontrib><creatorcontrib>Okada, Tohru</creatorcontrib><creatorcontrib>Kamada, Tadashi</creatorcontrib><creatorcontrib>Harada, Masaoki</creatorcontrib><creatorcontrib>Tsujii, Hirohiko</creatorcontrib><creatorcontrib>Shimazaki, Jun</creatorcontrib><title>Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>A novel risk assessment method, Japan Cancer of the Prostate Risk Assessment, has been developed based on database of patients receiving primary androgen deprivation therapy. To investigate the usefulness of Japan Cancer of the Prostate Risk Assessment for non-metastatic, high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Patients with non-metastatic, high-risk prostate cancer (T3, initial prostate specific antigen level ≥20 ng/ml, and/or Gleason score ≥8) were included. The patients were treated with carbon ion radiotherapy (the total dose from 57.6 Gy (relative biological effectiveness)/16 fractions to 66.0 Gy(relative biological effectiveness)/20 fractions), and neoadjuvant as well as adjuvant androgen deprivation therapy for at least 24 months.
Four hundred and twenty-six patients were included with the median follow-up of 68.1 months. Of 426, 210 (49.3%), 270 (63.4%) and 251 (58.9%) had Gleason 8-10, prostate specific antigen ≥20 ng/ml and T3, respectively. The 10-year progression-free and cause-specific survival rates in Japan Cancer of the Prostate Risk Assessment 1-2 group (76.5 and 98.9%) were significantly better than those in Japan Cancer of the Prostate Risk Assessment 3-6 group (52.6 and 93.1%), (P < 0.001 and P = 0.044, respectively). The median progression-free survivals in the Japan Cancer of the Prostate Risk Assessment 1-2 and 3-6 groups were 158.9 months and 125.9 months (95% confidence interval: 108.6-143.2 months), respectively.
For non-metastatic, high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy, Japan Cancer of the Prostate Risk Assessment score was useful for predicting the progression-free and cause-specific survivals.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Biomarkers, Tumor - blood</subject><subject>Chemotherapy, Adjuvant</subject><subject>Disease-Free Survival</subject><subject>Heavy Ion Radiotherapy</subject><subject>Humans</subject><subject>Japan</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy - methods</subject><subject>Neoplasm Grading</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><issn>0368-2811</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1r3DAQhkVoaLZpT7kXHQvFib4tHZelXyHQEJqzkeRx7K3XciQ5YX9C_nUVdtPDMDDz8DLzIHRBySUlhl9ttz5c9fuFEHWCVlQoWXHF6Du0IlzpimlKz9CHlLaEEKlF_R6dMSG1NJyu0Mt9gm4ZJ0gJhw5fV5v17d0aJx8i4C5E3A8PfRWH9BfPMaRsM2BvJw8RzzYPMOWEc4QybvHzkPuyjC5MeCgVbTuE3EO08x7P45KwndoYHmDCLcxxeCoBBTsSH9FpZ8cEn479HN1___Zn87O6-f3j12Z9U3luRK6sE53RyjMKUprWMF17qC11UhsHhknOW8mcq5XwHVNeO6YUN1QL540Qmp-jL4fc8s_jAik3uyF5GEc7QVhSQyVlUqq6JgX9ekB9eT1F6Jpy9c7GfUNJ8-q-eXXfHNwX-vMxeHE7aP-zb7L5P9Vbg0g</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Akakura, Koichiro</creator><creator>Tsuji, Hiroshi</creator><creator>Suzuki, Hiroyoshi</creator><creator>Ichikawa, Tomohiko</creator><creator>Ishikawa, Hitoshi</creator><creator>Okada, Tohru</creator><creator>Kamada, Tadashi</creator><creator>Harada, Masaoki</creator><creator>Tsujii, Hirohiko</creator><creator>Shimazaki, Jun</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140401</creationdate><title>Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy</title><author>Akakura, Koichiro ; Tsuji, Hiroshi ; Suzuki, Hiroyoshi ; Ichikawa, Tomohiko ; Ishikawa, Hitoshi ; Okada, Tohru ; Kamada, Tadashi ; Harada, Masaoki ; Tsujii, Hirohiko ; Shimazaki, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-ab4f986c21e559d9287ce7a1b589be92533d52bb764cf26c8b26639184bc94483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Biomarkers, Tumor - blood</topic><topic>Chemotherapy, Adjuvant</topic><topic>Disease-Free Survival</topic><topic>Heavy Ion Radiotherapy</topic><topic>Humans</topic><topic>Japan</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy - methods</topic><topic>Neoplasm Grading</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akakura, Koichiro</creatorcontrib><creatorcontrib>Tsuji, Hiroshi</creatorcontrib><creatorcontrib>Suzuki, Hiroyoshi</creatorcontrib><creatorcontrib>Ichikawa, Tomohiko</creatorcontrib><creatorcontrib>Ishikawa, Hitoshi</creatorcontrib><creatorcontrib>Okada, Tohru</creatorcontrib><creatorcontrib>Kamada, Tadashi</creatorcontrib><creatorcontrib>Harada, Masaoki</creatorcontrib><creatorcontrib>Tsujii, Hirohiko</creatorcontrib><creatorcontrib>Shimazaki, Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akakura, Koichiro</au><au>Tsuji, Hiroshi</au><au>Suzuki, Hiroyoshi</au><au>Ichikawa, Tomohiko</au><au>Ishikawa, Hitoshi</au><au>Okada, Tohru</au><au>Kamada, Tadashi</au><au>Harada, Masaoki</au><au>Tsujii, Hirohiko</au><au>Shimazaki, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>44</volume><issue>4</issue><spage>360</spage><epage>365</epage><pages>360-365</pages><issn>0368-2811</issn><eissn>1465-3621</eissn><abstract>A novel risk assessment method, Japan Cancer of the Prostate Risk Assessment, has been developed based on database of patients receiving primary androgen deprivation therapy. To investigate the usefulness of Japan Cancer of the Prostate Risk Assessment for non-metastatic, high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Patients with non-metastatic, high-risk prostate cancer (T3, initial prostate specific antigen level ≥20 ng/ml, and/or Gleason score ≥8) were included. The patients were treated with carbon ion radiotherapy (the total dose from 57.6 Gy (relative biological effectiveness)/16 fractions to 66.0 Gy(relative biological effectiveness)/20 fractions), and neoadjuvant as well as adjuvant androgen deprivation therapy for at least 24 months.
Four hundred and twenty-six patients were included with the median follow-up of 68.1 months. Of 426, 210 (49.3%), 270 (63.4%) and 251 (58.9%) had Gleason 8-10, prostate specific antigen ≥20 ng/ml and T3, respectively. The 10-year progression-free and cause-specific survival rates in Japan Cancer of the Prostate Risk Assessment 1-2 group (76.5 and 98.9%) were significantly better than those in Japan Cancer of the Prostate Risk Assessment 3-6 group (52.6 and 93.1%), (P < 0.001 and P = 0.044, respectively). The median progression-free survivals in the Japan Cancer of the Prostate Risk Assessment 1-2 and 3-6 groups were 158.9 months and 125.9 months (95% confidence interval: 108.6-143.2 months), respectively.
For non-metastatic, high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy, Japan Cancer of the Prostate Risk Assessment score was useful for predicting the progression-free and cause-specific survivals.</abstract><cop>England</cop><pmid>24585931</pmid><doi>10.1093/jjco/hyu006</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0368-2811 |
| ispartof | Japanese journal of clinical oncology, 2014-04, Vol.44 (4), p.360-365 |
| issn | 0368-2811 1465-3621 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1512556770 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Androgen Antagonists - therapeutic use Antineoplastic Agents, Hormonal - therapeutic use Biomarkers, Tumor - blood Chemotherapy, Adjuvant Disease-Free Survival Heavy Ion Radiotherapy Humans Japan Kaplan-Meier Estimate Male Middle Aged Neoadjuvant Therapy - methods Neoplasm Grading Predictive Value of Tests Prognosis Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - therapy Risk Assessment Risk Factors |
| title | Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T21%3A06%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Usefulness%20of%20J-CAPRA%20score%20for%20high-risk%20prostate%20cancer%20patients%20treated%20with%20carbon%20ion%20radiotherapy%20plus%20androgen%20deprivation%20therapy&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Akakura,%20Koichiro&rft.date=2014-04-01&rft.volume=44&rft.issue=4&rft.spage=360&rft.epage=365&rft.pages=360-365&rft.issn=0368-2811&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hyu006&rft_dat=%3Cproquest_cross%3E1512556770%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1512556770&rft_id=info:pmid/24585931&rfr_iscdi=true |